Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Borrelia miyamotoi Infection in Patients from Upper Midwestern United States, 2014-2015.

Jobe DA, Lovrich SD, Oldenburg DG, Kowalski TJ, Callister SM.

Emerg Infect Dis. 2016 Aug;22(8):1471-3. doi: 10.3201/eid2208.151878.

2.

The Emergence of Clinically Relevant Babesiosis in Southwestern Wisconsin.

Kowalski TJ, Jobe DA, Dolan EC, Kessler A, Lovrich SD, Callister SM.

WMJ. 2015 Aug;114(4):152-7.

3.

Antibody responses to Borrelia burgdorferi outer surface proteins C and F in experimentally infected Beagle dogs.

Callister SM, LaFleur RL, Jobe DA, Lovrich SD, Wasmoen TL.

J Vet Diagn Invest. 2015 Jul;27(4):526-30. doi: 10.1177/1040638715583868. Epub 2015 Jun 11.

PMID:
26069225
4.

Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.

LaFleur RL, Callister SM, Dant JC, Wasmoen TL, Jobe DA, Lovrich SD.

Clin Vaccine Immunol. 2015 Jul;22(7):836-9. doi: 10.1128/CVI.00193-15. Epub 2015 May 13.

5.

Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population.

Agger WA, Siddiqui D, Lovrich SD, Callister SM, Borgert AJ, Merkitch KW, Mason TC, Baumgardner DJ, Burmester JK, Shukla SK, Welter JD, Stewart KS, Washburn MJ, Bailey HH.

Obstet Gynecol. 2014 Nov;124(5):969-77. doi: 10.1097/AOG.0000000000000470.

6.

OmpR regulation of the uropathogenic Escherichia coli fimB gene in an acidic/high osmolality environment.

Rentschler AE, Lovrich SD, Fitton R, Enos-Berlage J, Schwan WR.

Microbiology. 2013 Feb;159(Pt 2):316-27. doi: 10.1099/mic.0.059386-0. Epub 2012 Nov 22.

7.

Comparative whole-genome mapping to determine Staphylococcus aureus genome size, virulence motifs, and clonality.

Shukla SK, Pantrangi M, Stahl B, Briska AM, Stemper ME, Wagner TK, Zentz EB, Callister SM, Lovrich SD, Henkhaus JK, Dykes CW.

J Clin Microbiol. 2012 Nov;50(11):3526-33. doi: 10.1128/JCM.01168-12. Epub 2012 Aug 22.

8.

Expansion of the Midwestern focus for human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin.

Lovrich SD, Jobe DA, Kowalski TJ, Policepatil SM, Callister SM.

J Clin Microbiol. 2011 Nov;49(11):3855-9. doi: 10.1128/JCM.05025-11. Epub 2011 Sep 14.

9.

Rapid decline of OspC borreliacidal antibodies following treatment of patients with early Lyme disease.

Jobe DA, Kowalski TJ, Bloemke M, Lovrich SD, Callister SM.

Clin Vaccine Immunol. 2011 Jun;18(6):1034-7. doi: 10.1128/CVI.00063-11. Epub 2011 Apr 20.

10.

Use of optical mapping to sort uropathogenic Escherichia coli strains into distinct subgroups.

Schwan WR, Briska A, Stahl B, Wagner TK, Zentz E, Henkhaus J, Lovrich SD, Agger WA, Callister SM, DuChateau B, Dykes CW.

Microbiology. 2010 Jul;156(Pt 7):2124-35. doi: 10.1099/mic.0.033977-0. Epub 2010 Apr 8.

11.

One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.

LaFleur RL, Callister SM, Dant JC, Jobe DA, Lovrich SD, Warner TF, Wasmoen TL, Schell RF.

Clin Vaccine Immunol. 2010 May;17(5):870-4. doi: 10.1128/CVI.00524-09. Epub 2010 Mar 17.

12.

Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.

Pingali SR, Mathiason MA, Lovrich SD, Go RS.

Clin Lymphoma Myeloma. 2009 Oct;9(5):E25-9. doi: 10.3816/CLM.2009.n.080.

PMID:
19858050
13.

Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF.

Clin Vaccine Immunol. 2009 Feb;16(2):253-9. doi: 10.1128/CVI.00373-08. Epub 2008 Dec 3.

14.

Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC.

Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2008 Jun;15(6):981-5. doi: 10.1128/CVI.00079-08. Epub 2008 Apr 16.

15.

Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Lovrich SD, La Fleur RL, Jobe DA, Johnson JC, Asp KE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2007 May;14(5):635-7. Epub 2007 Mar 7.

16.

Borrelia burgdorferi in Ixodes scapularis ticks, Chicago area.

Jobe DA, Lovrich SD, Nelson JA, Velat TC, Anchor C, Koeune T, Martin SA Jr.

Emerg Infect Dis. 2006 Jun;12(6):1039-41. No abstract available.

17.

Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Lovrich SD, Jobe DA, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2005 Jun;12(6):746-51. Erratum in: Clin Diagn Lab Immunol. 2005 Sep;12(9):1139.

18.

Human cyclic thrombocytopenia and Anaplasma spp. infection.

Go RS, Lovrich SD, Callister SM, Meyer LA, Bottner WA, Farnen JP.

Eur J Haematol. 2005 Feb;74(2):182-3. No abstract available.

PMID:
15654914
19.

High prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, Wisconsin.

Schlicht MJ, Lovrich SD, Sartin JS, Karpinsky P, Callister SM, Agger WA.

J Clin Microbiol. 2004 Oct;42(10):4636-40.

20.

C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Jobe DA, Lovrich SD, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2003 Jul;10(4):573-8.

21.

Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA.

Clin Diagn Lab Immunol. 2002 Jul;9(4):908-12.

22.

Reassessment of a midwestern Lyme disease focus for Borrelia burgdorferi and the human granulocytic ehrlichiosis agent.

Jackson CA, Lovrich SD, Agger WA, Callister SM.

J Clin Microbiol. 2002 Jun;40(6):2070-3.

23.

Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody.

Remington MC, Munson EL, Callister SM, Molitor ML, Christopherson JA, DeCoster DJ, Lovrich SD, Schell RF.

Infect Immun. 2001 Jul;69(7):4268-75.

24.

Detection of borreliacidal antibodies in dogs after challenge with Borrelia burgdorferi-infected ixodes scapularis ticks.

Callister SM, Jobe DA, Schell RF, Lovrich SD, Onheiber KL, Korshus JB.

J Clin Microbiol. 2000 Oct;38(10):3670-4.

25.

Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Munson EL, Du Chateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF.

Infect Immun. 2000 Oct;68(10):5496-501.

26.

Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi.

Croke CL, Munson EL, Lovrich SD, Christopherson JA, Remington MC, England DM, Callister SM, Schell RF.

Infect Immun. 2000 Feb;68(2):658-63.

27.

Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Wieneke CA, Lovrich SD, Callister SM, Jobe DA, Marks JA, Schell RF.

J Clin Microbiol. 2000 Jan;38(1):313-7.

28.

Macrophages interact with enriched populations of distinct T lymphocyte subsets for the induction of severe destructive Lyme arthritis.

DuChateau BK, Munson EL, England DM, Lovrich SD, Callister SM, Jensen JR, Schell RF.

J Leukoc Biol. 1999 Feb;65(2):162-70.

PMID:
10088598
29.

Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA.

J Infect Dis. 1998 Sep;178(3):733-41.

PMID:
9728542
30.

Enhanced sensitivity of the borreliacidal-antibody test.

Callister SM, Schell RF, Lovrich SD.

Mayo Clin Proc. 1997 Nov;72(11):1093-4. No abstract available.

PMID:
9374987
31.

Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis.

DuChateau BK, Jensen JR, England DM, Callister SM, Lovrich SD, Schell RF.

Infect Immun. 1997 Jul;65(7):2829-36.

32.

Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.

Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Lovrich SD, DuChateau BK, Jensen JR.

J Infect Dis. 1996 Oct;174(4):739-46.

PMID:
8843211
33.

Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD.

Clin Diagn Lab Immunol. 1996 Jul;3(4):399-402.

34.

Macrophages exposed to Borrelia burgdorferi induce Lyme arthritis in hamsters.

Du Chateau BK, England DM, Callister SM, Lim LC, Lovrich SD, Schell RF.

Infect Immun. 1996 Jul;64(7):2540-7.

35.

Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.

Lovrich SD, Callister SM, DuChateau BK, Lim LC, Winfrey J, Day SP, Schell RF.

Infect Immun. 1995 Jun;63(6):2113-9.

36.

Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe.

Lovrich SD, Callister SM, Lim LC, DuChateau BK, Schell RF.

J Infect Dis. 1994 Jul;170(1):115-21.

PMID:
8014485
37.

Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi.

Lim LC, England DM, DuChateau BK, Glowacki NJ, Creson JR, Lovrich SD, Callister SM, Jobe DA, Schell RF.

Infect Immun. 1994 Jul;62(7):2825-33.

38.

Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.

Jobe DA, Callister SM, Lim LC, Lovrich SD, Schell RF.

J Clin Microbiol. 1994 Mar;32(3):618-22.

39.

Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Liu YF, Lim LC, Schell K, Lovrich SD, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 1994 Mar;1(2):145-9.

40.

Lyme disease: laboratory diagnosis and serologic testing.

Callister SM, Schell RF, Lovrich SD, Jobe DA.

Endeavour. 1994;18(2):80-4. Review.

PMID:
7520388
41.

Detection of borreliacidal antibody by using acridine orange and flow cytometry.

Lim LC, Liu YF, Schell K, Lovrich SD, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 1994 Jan;1(1):44-50.

42.

Seroprotective groups among isolates of Borrelia burgdorferi.

Lovrich SD, Callister SM, Lim LC, Schell RF.

Infect Immun. 1993 Oct;61(10):4367-74.

43.

Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.

Callister SM, Schell RF, Case KL, Lovrich SD, Day SP.

J Infect Dis. 1993 Jan;167(1):158-64.

PMID:
8418162
44.

Immunoglobulin G2 confers protection against Borrelia burgdorferi infection in LSH hamsters.

Schmitz JL, Schell RF, Callister SM, Lovrich SD, Day SP, Coe JE.

Infect Immun. 1992 Jul;60(7):2677-82.

45.

Depletion of complement and effects on passive transfer of resistance to infection with Borrelia burgdorferi.

Schmitz JL, Lovrich SD, Callister SM, Schell RF.

Infect Immun. 1991 Oct;59(10):3815-8.

46.

Lyme disease assay which detects killed Borrelia burgdorferi.

Callister SM, Schell RF, Lovrich SD.

J Clin Microbiol. 1991 Sep;29(9):1773-6.

47.

Borreliacidal activity of sera from hamsters infected with the Lyme disease spirochete.

Lovrich SD, Callister SM, Schmitz JL, Alder JD, Schell RF.

Infect Immun. 1991 Aug;59(8):2522-8.

48.

Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters.

Schmitz JL, Schell RF, Lovrich SD, Callister SM, Coe JE.

Infect Immun. 1991 Jun;59(6):1916-21.

Supplemental Content

Loading ...
Support Center